Fosmidomycin
Star0
Identification
- Generic Name
- Fosmidomycin
- DrugBank Accession Number
- DB02948
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Structure
- Weight
- Average: 183.0997
Monoisotopic: 183.029658947 - Chemical Formula
- C4H10NO5P
- Synonyms
- Fosmidomycin
- Fosmidomycina
- Fosmidomycine
- Fosmidomycinum
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism U1-deoxy-D-xylulose 5-phosphate reductoisomerase Not Available Escherichia coli (strain K12) - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcenocoumarol The risk or severity of bleeding can be increased when Fosmidomycin is combined with Acenocoumarol. Ambroxol The risk or severity of methemoglobinemia can be increased when Fosmidomycin is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Fosmidomycin is combined with Articaine. BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Fosmidomycin. Benzocaine The risk or severity of methemoglobinemia can be increased when Fosmidomycin is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Fosmidomycin is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Fosmidomycin is combined with Bupivacaine. Butacaine The risk or severity of methemoglobinemia can be increased when Fosmidomycin is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Fosmidomycin is combined with Butamben. Capsaicin The risk or severity of methemoglobinemia can be increased when Fosmidomycin is combined with Capsaicin. Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Fosmidomycin sodium IYI1EW66CX 66508-37-0 ZZPUYRHMTGOTEU-UHFFFAOYSA-M
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as organic phosphonic acids. These are organic compounds containing phosphonic acid.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Organic phosphonic acids and derivatives
- Sub Class
- Organic phosphonic acids
- Direct Parent
- Organic phosphonic acids
- Alternative Parents
- Hydroxamic acids / Organopnictogen compounds / Organophosphorus compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Aliphatic acyclic compound / Carbonyl group / Carboxylic acid derivative / Hydrocarbon derivative / Hydroxamic acid / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound / Organooxygen compound
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- phosphonic acids, hydroxamic acid (CHEBI:443725)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5829E3D9I9
- CAS number
- 66508-53-0
- InChI Key
- GJXWDTUCERCKIX-UHFFFAOYSA-N
- InChI
- InChI=1S/C4H10NO5P/c6-4-5(7)2-1-3-11(8,9)10/h4,7H,1-3H2,(H2,8,9,10)
- IUPAC Name
- [3-(N-hydroxyformamido)propyl]phosphonic acid
- SMILES
- ON(CCCP(O)(O)=O)C=O
References
- General References
- Not Available
- External Links
- PubChem Compound
- 572
- PubChem Substance
- 46508936
- ChemSpider
- 555
- BindingDB
- 50153713
- ChEBI
- 443725
- ChEMBL
- CHEMBL203125
- ZINC
- ZINC000012502867
- Therapeutic Targets Database
- DAP001384
- PDBe Ligand
- FOM
- Wikipedia
- Fosmidomycin
- PDB Entries
- 1onp / 1q0h / 1q0l / 2egh / 2jcv / 2jcx / 3a06 / 3au9 / 3upy / 4aic … show 6 more
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Malaria 1 2 Completed Treatment Malaria 2 2 Unknown Status Treatment Malaria 2 2 Unknown Status Treatment Oral Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria 1 2 Withdrawn Treatment Malaria 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 21.9 mg/mL ALOGPS logP -1.1 ALOGPS logP -2.2 Chemaxon logS -0.92 ALOGPS pKa (Strongest Acidic) 1.81 Chemaxon pKa (Strongest Basic) -5.6 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 98.07 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 36.83 m3·mol-1 Chemaxon Polarizability 15.06 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.9277 Blood Brain Barrier + 0.9098 Caco-2 permeable - 0.6781 P-glycoprotein substrate Non-substrate 0.6815 P-glycoprotein inhibitor I Non-inhibitor 0.9025 P-glycoprotein inhibitor II Non-inhibitor 0.9359 Renal organic cation transporter Non-inhibitor 0.9023 CYP450 2C9 substrate Non-substrate 0.7726 CYP450 2D6 substrate Non-substrate 0.8081 CYP450 3A4 substrate Non-substrate 0.5727 CYP450 1A2 substrate Non-inhibitor 0.7958 CYP450 2C9 inhibitor Non-inhibitor 0.856 CYP450 2D6 inhibitor Non-inhibitor 0.9187 CYP450 2C19 inhibitor Non-inhibitor 0.8218 CYP450 3A4 inhibitor Non-inhibitor 0.6376 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9611 Ames test AMES toxic 0.5096 Carcinogenicity Non-carcinogens 0.6785 Biodegradation Not ready biodegradable 0.7712 Rat acute toxicity 2.2352 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9383 hERG inhibition (predictor II) Non-inhibitor 0.869
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Unknown
- General Function
- Nadph binding
- Specific Function
- Catalyzes the NADP-dependent rearrangement and reduction of 1-deoxy-D-xylulose-5-phosphate (DXP) to 2-C-methyl-D-erythritol 4-phosphate (MEP).
- Gene Name
- dxr
- Uniprot ID
- P45568
- Uniprot Name
- 1-deoxy-D-xylulose 5-phosphate reductoisomerase
- Molecular Weight
- 43387.575 Da
References
Drug created at June 13, 2005 13:24 / Updated at February 21, 2021 18:51